Brigham and Women’s nurses ratify contract, avoid strike

Unionized nurses at Boston’s Brigham and Women’s Hospital have ratified a new three-year labor contract, avoiding what would have been the largest nurses strike in Massachusetts history.

The Massachusetts Nurses Association (MNA), which represents more than 3,300 nurses at Brigham, said July 20 that its members “voted overwhelmingly” in favor of a tentative agreement which had first been reached on June 26, just before a planned one-day strike.

“The ratification of this new contract leaves no doubt that front-line nurses can and should stand up for safe patient care and professional respect,” said Kelly Morgan, a labor and delivery nurse and vice chair of the MNA Bargaining Unit. “When a health care employer recognizes that a unionized workplace is a democratic and productive workplace, patients are protected and nurses’ voices are heard.”

Hospital president Elizabeth G. Nabel, MD, called the labor talks “logistically and emotionally challenging for every member of the Brigham community,” and said the hospital is glad to put the negotiations “behind us.”

Contract disputes haven’t been settled at another Brigham hospital, the 150-bed Faulkner Hospital. A separate bargaining unit of nurses will hold an informational picket July 22 for two hours, involving only nurses who aren’t scheduled to work at that time. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.